Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 2 6Phase 1 5Phase 1/2 1

Status

Recruiting 3Unknown 2Withdrawn 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 1NET 1Endocrine 1

Conditions

Cholangiocarcinoma 2Sarcoma 1Recurrence 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Yttrium-90 × Clear all
NCT04339036 2026-06-04

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
70 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05620771 2026-05-26

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Northwestern University

Phase 2 Recruiting
200 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Beth Israel Deaconess Medical Center

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT06375915 2024-05-24

PM-CARE

IRCCS San Raffaele

Phase 2 Unknown
33 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT01898962 2013-07-15

Definitive Therapy for Oligometastatic Solid Malignancies

Rocky Mountain Cancer Centers

Phase 2 Unknown
110 enrolled
Sarcoma

Neoplasm Metastasis, Recurrence, Sarcoma

NCT00766220 2013-01-03

Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡